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PP-112 Analysis of ﬁve HBeAg-positive patients with
Chinese herb Kuanxiongjiedu grain anti-HBV
infection treatment
Lequan Min*,1, Yanling Liu2, Jianghe Wang2, Huiwen Hong2,
Suyun Ma2. 1University of Science and Technology Beijing;
2Beijing Xiyuan Hospital, Chinese Traditional Medical Research
Institute of China
Background and objectives: The objectives of the research are
to observe the efﬁcacy of the Chinese Herb Kuanxiongjiedu Grain
(CHKG, consists of 12 ingredients) treatment for the patients
whose HBV DNA levels over 106 copies/mL and analysis the
variations of the patients’ hepatocyte.
Methods: Five patients with HBeAg-positive are selected. They
have baseline ALTs: 22.3∼285U/L, HBV DNAs: 2.1×106∼2.8×108
copies/mL. The patients received CHKG two times daily (24g
each time) for 32 weeks. The ALT and HBV DNA tests were
implemented every two weeks in the ﬁrst three months, and
taken every four weeks in the following months. A Ultrasound
Scanner was used to scan the patients and a normal person’s
livers. The mean and standard deviation of the gray levels of the
normal person’s scanned liver image are selected as the standard
of normal liver.
Results: At the week 32, one patient’s HBV DNA was below 1000
copies/mL and had normal ALT; three patient’s HBV DNAs and
ALTs have no signiﬁcant changes; one patient’s HBV DNAs have
signiﬁcant changes. Except the ﬁrst patient, the patients’ normal
liver pixels increased 14% ∼ 51%.
Conclusion: The CHKG may help to recovered the chronic HBV
patients’ damaged hepatocyte even the patients’ virus levels
were not be suppressed during the therapy. Further investigation
should be implemented.
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PP-113 Sequence analysis and replication ﬁtness of the
complete hepatitis B virus genome in patients
with chronic hepatitis B
Dong Ji *, Yan Liu. Viral Hepatitis Research Laboratory, Institute
of Infectious Diseases, 302 Hospital of PLA, Beijing, China
Objective: To analyze the complete HBV genome in patients and
evaluate its replication capacity.
Fig. 1. Schematic diagram of the point mutations analyzed in the study. In
the ﬁrst part of the ﬁgure, the nunber on the top of the full HBV genome
refers to the EcoRI site (3215/0). Position of the four open reading frames
(ORFs) encoding preC/core, preS1/preS2/S, polymerase (Pol), and X protein
are shown by the gray rectangle and the arrow indicates the transcription
direction. The four cis-elements (enhancers and promoters) are indicated
by the open triangle. The numbers under the full HBV genome represent the
nucleotide positions of the studied mutations. In the second part of the
ﬁgure are listed amino acid mutations in both polymerase (RT domain) and
envelope genes-associated domains (S domain).
Methods: The full-length HBV genome ampliﬁcation, cloning,
and sequencing were preformed. Genotype and mutation sites
related to antiviral agents were analyzed, and site-directed mu-
tagenesis was performed on interested sites. The full-length HBV
genomes were transfected into HepG2 and Huh-7 cell lines. 72 h
after transfection, expression of HBsAg was detected with ELISA,
quantitation of intracellular HBV replicative intermediates were
examined by qPCR.
Results: 12 different clones were obtained. several mutation
sites, such as A181V/S, V84M, were identiﬁed, and the better
management of 5 patients was developed.
Fig. 2. Relative replication yield of HBV mutants.
Conclusion: Vector-free replication assay is an approach to
determine the phenotype of clinical HBV strains, which could be-
come an important tool for the management of patient infected
with HBV.
PP-114 Correlation factors involved in therapeutic
efﬁcacy of adefovir dipivoxil for chronic hepatitis
B with YMDD mutation
Yuan-wang Qiu*, Xiang-hu Jiang, Li-hua Huang. Wuxi Infectious
Disease Hospital
Background: To investigate the correlation factors associated
with the therapeutic efﬁcacy of adefovir dipivoxil for chronic
hepatitis B with YMDD mutation.
Methods: 92 patients were enrolled and treated with adefovir
dipivoxil for 48 weeks, Logistic regression analysis was used
to identify some possible correlation factors associated with
therapeutic efﬁcacy.
Results: Patients who achieved undetectable HBV DNA at week
48 of the treatment were found to have a lower baseline HBV
DNA levels compared with those who did not achieve,and the
same result in patients who achieved HBeAg seroconversion
and serum alanine aminotransferase (ALT) normalization. There
were signiﬁcant difference between patients whose baseline ALT
levels ≤1 ULN,HBV DNA levels ≤5.0 lgcopies/mL and patients
whose baseline serum ALT levels >1 ULN,HBV DNA levels >5.0
lgcopies/mL in undetectable HBV DNA (χ2=17.321, P<0.001),
HBeAg seroconversion (χ2=3.88, P=0.049) and ALT normalization
rates (χ2=25.526, P<0.001) after 48-week treatment. Logistic
regression analysis indicated the baseline HBV DNA levels, unde-
tectable serum HBV DNA by PCR at week 24, and undetectable
serum YMDD mutation at week 12 were correlation factors of
therapeutic efﬁcacy at week 48.
Conclusion: Better response at week 48 has signiﬁcantly asso-
